Developer docs
API playgroundTry for free, no card

Search company profiles

Arboretum Ventures

Full company profile

uuid00003aw

Namestring
Arboretum Ventures
Legal namestring
Arboretum Ventures, Inc.
Websiteurl
arboretumvc.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Arboretum Ventures, Inc. is a healthcare-focused venture capital firm headquartered at 201 S Main St., Suite 300, Ann Arbor, Michigan, founded in 2002 by Jan Garfinkle. The firm invests in early-stage (primarily Series A and B) healthcare companies across four verticals: medical devices, life sciences tools and diagnostics, tech-enabled care delivery, and pharma adjacencies. Over 20-plus years the firm has grown to manage $1 billion in assets under management across six funds, with 76% of its portfolio invested in under-ventured geographies and sectors — predominantly the Midwest — and reports that portfolio companies have impacted 16 million-plus patient lives.

The firm generates revenue through the standard venture capital two-stream model: recurring management fees on committed capital (typically ~2% of AUM) charged to institutional Limited Partners such as pension funds, endowments, and family offices, supplemented by carried interest (typically 20% of fund profits above the hurdle rate) realized on successful exits. Investment terms are privately negotiated and not publicly disclosed. The firm operates a sales-led, relationship-driven go-to-market, accessing deal flow through its 20-plus-year network of healthcare entrepreneurs, executives, co-investors, and a 10-plus-member advisory board of C-level industry executives.

Arboretum's investment team is led by Founder & Managing Partner Jan Garfinkle alongside Managing Partners Tom Shehab, Paul McCreadie (also COO), and Jeff Terrell (promoted May 2026), supported by Partners, a Venture Partner, Principals, Associates, an Analyst, and a finance/admin function including CFO Marcy Marshall, SVP of Finance Amanda Elder, and Controller Evan McClelland (joined 2025). The portfolio includes Akadeum Life Sciences, Allay Therapeutics, ArborMetrix, AtaCor Medical, Convergent Dental, Endogenex, Flosonics Medical, Francis Medical, Koya Medical, Motif Neurotech, Pharaoh Neuro, and Virtual Incision, among others. Notable exits include NeuMoDx (acquired by QIAGEN, 2020), NxThera (acquired by Boston Scientific, 2018), CardioMEMS (acquired by St. Jude Medical, 2014), and IPOs including SI-BONE (2018), Esperion Therapeutics (2013), and Inogen (2014).

Short descriptiontext

Arboretum Ventures is a Michigan-based healthcare venture capital firm managing $1 billion across six funds, investing in early-stage Series A and B companies in medical devices, life sciences tools and diagnostics, tech-enabled care delivery, and pharma adjacencies, primarily in under-ventured U.S. Midwest geographies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAnn Arbor, United States
HQ citystring
Ann Arbor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, early-stage medical device investment, life sciences venture funding, healthcare startup financing, tech-enabled care delivery investment
Industry1 code
PRIMARYFSANAAAL
Venture Debt Providers
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

VC firms typically charge management fees on committed capital (typically 2% of AUM) from their Limited Partners (LPs).

2Carried Interest (Carry)
TypeTransaction Fee
Description

Performance-based profit participation (typically 20% of fund profits above the hurdle rate) distributed to the General Partner upon successful exits.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Arboretum Ventures is a Michigan-based venture capital firm that provides early-stage (Series A and B) growth capital to healthcare companies across four sectors: Medical Devices, Life Science Tools & Diagnostics, Tech-Enabled Care Delivery, and Pharma Adjacencies. The firm manages $1B across six funds, deploys capital primarily into under-ventured geographies, and provides strategic guidance, board participation, and network access to portfolio companies. Capital is sourced from institutional Limited Partners (pension funds, endowments, family offices) via multi-year fund commitments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 16M+ patient lives impacted by portfolio companies
+2 more records
Product and service2 records
1Healthcare Venture Capital Investment Services
CategoryHealthcare Venture Capital
2Limited Partner Fund Management Services
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mid-size healthcare-focused VC firm based in Durham, NC that invests in early-stage biotech, medtech, and health IT companies. Directly comparable to Arboretum given similar stage focus, fund size, and prior co-investment in Pharaoh Neuro's $20M Series A.

TypeDirect peer
Description

Healthcare-focused investment firm with multi-strategy private and public healthcare exposure. Comparable to Arboretum as a healthcare-dedicated investor that co-invested in Strata Oncology's Series B and shares the same sector specialization.

TypeDirect peer
Description

Private equity and venture arm of Robert W. Baird with a dedicated healthcare practice. Comparable stage and sector focus, and participated as a co-investor alongside Arboretum in Strata Oncology's $26M Series B.

TypeDirect peer
Description

Healthcare-focused VC firm based in San Diego investing in medical devices, biopharma, and diagnostics. Directly comparable specialty and stage; Arboretum's Venture Partner Nicole Vitullo previously spent 20+ years at Domain.

TypeRegional player
Description

Michigan-based venture capital fund of funds and co-investor that participated in Strata Oncology's Series B alongside Arboretum. Comparable as a regional Michigan investor with healthcare exposure but operates more as a fund-of-funds.

TypeDirect peer
Description

Boston and London-based healthcare VC firm investing across biotech, medical devices, and health tech. Comparable stage and sector focus as Arboretum with similar fund size and Series A/B orientation.

TypeBroad incumbent
Description

One of the largest US venture firms with a substantial healthcare and life sciences practice. Comparable sector focus but materially larger AUM and broader stage range than Arboretum.

TypeBroad incumbent
Description

Healthcare and technology VC firm with deep life sciences and biotech franchise. Comparable as a healthcare specialist but operates at materially larger fund sizes than Arboretum.

TypeBroad incumbent
Description

Corporate venture arm of Pfizer investing in early-stage biotech, medtech, and digital health. Co-investor with Arboretum in Strata Oncology's Series B; broader portfolio and significantly larger check capacity.

TypeBroad incumbent
Description

Corporate venture arm of Merck investing across digital health, health tech, and life sciences. Co-investor alongside Arboretum in Strata Oncology's Series B; operates at far larger scale as a strategic CVC.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment115 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arboretum Ventures

Healthcare Venture Capitalarboretumvc.com

Arboretum Ventures is a Michigan-based healthcare venture capital firm managing $1 billion across six funds, investing in early-stage Series A and B companies in medical devices, life sciences tools and diagnostics, tech-enabled care delivery, and pharma adjacencies, primarily in under-ventured U.S. Midwest geographies.

What Arboretum Ventures does

Arboretum Ventures, Inc. is a healthcare-focused venture capital firm headquartered at 201 S Main St., Suite 300, Ann Arbor, Michigan, founded in 2002 by Jan Garfinkle. The firm invests in early-stage (primarily Series A and B) healthcare companies across four verticals: medical devices, life sciences tools and diagnostics, tech-enabled care delivery, and pharma adjacencies. Over 20-plus years the firm has grown to manage $1 billion in assets under management across six funds, with 76% of its portfolio invested in under-ventured geographies and sectors — predominantly the Midwest — and reports that portfolio companies have impacted 16 million-plus patient lives.

The firm generates revenue through the standard venture capital two-stream model: recurring management fees on committed capital (typically ~2% of AUM) charged to institutional Limited Partners such as pension funds, endowments, and family offices, supplemented by carried interest (typically 20% of fund profits above the hurdle rate) realized on successful exits. Investment terms are privately negotiated and not publicly disclosed. The firm operates a sales-led, relationship-driven go-to-market, accessing deal flow through its 20-plus-year network of healthcare entrepreneurs, executives, co-investors, and a 10-plus-member advisory board of C-level industry executives.

Arboretum's investment team is led by Founder & Managing Partner Jan Garfinkle alongside Managing Partners Tom Shehab, Paul McCreadie (also COO), and Jeff Terrell (promoted May 2026), supported by Partners, a Venture Partner, Principals, Associates, an Analyst, and a finance/admin function including CFO Marcy Marshall, SVP of Finance Amanda Elder, and Controller Evan McClelland (joined 2025). The portfolio includes Akadeum Life Sciences, Allay Therapeutics, ArborMetrix, AtaCor Medical, Convergent Dental, Endogenex, Flosonics Medical, Francis Medical, Koya Medical, Motif Neurotech, Pharaoh Neuro, and Virtual Incision, among others. Notable exits include NeuMoDx (acquired by QIAGEN, 2020), NxThera (acquired by Boston Scientific, 2018), CardioMEMS (acquired by St. Jude Medical, 2014), and IPOs including SI-BONE (2018), Esperion Therapeutics (2013), and Inogen (2014).

Arboretum Ventures firmographics

Firmographics
Name
Arboretum Ventures
Legal name
Arboretum Ventures, Inc.
Website
https://arboretumvc.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
Arboretum Ventures is a Michigan-based healthcare venture capital firm managing $1 billion across six funds, investing in early-stage Series A and B companies in medical devices, life sciences tools and diagnostics, tech-enabled care delivery, and pharma adjacencies, primarily in under-ventured U.S. Midwest geographies.
Ownership category
akta.pro rank

Arboretum Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAL
Venture Debt Providers

Keywords

  • Healthcare venture capital
  • Early-stage medical device investment
  • Life sciences venture funding
  • Healthcare startup financing
  • Tech-enabled care delivery investment

Where Arboretum Ventures is headquartered

Location

Headquarters

HQ city
Ann Arbor
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Arboretum Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Management Fees: VC firms typically charge management fees on committed capital (typically 2% of AUM) from their Limited Partners (LPs).
  2. Carried Interest (Carry): Performance-based profit participation (typically 20% of fund profits above the hurdle rate) distributed to the General Partner upon successful exits.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Arboretum Ventures product offering

Product offering

Core offering

Arboretum Ventures is a Michigan-based venture capital firm that provides early-stage (Series A and B) growth capital to healthcare companies across four sectors: Medical Devices, Life Science Tools & Diagnostics, Tech-Enabled Care Delivery, and Pharma Adjacencies. The firm manages $1B across six funds, deploys capital primarily into under-ventured geographies, and provides strategic guidance, board participation, and network access to portfolio companies. Capital is sourced from institutional Limited Partners (pension funds, endowments, family offices) via multi-year fund commitments.

Differentiator

Problem solved

Functional benefit

Products and services

  • Healthcare Venture Capital Investment Services
  • Limited Partner Fund Management Services

Quantifiable outcome

  • 16M+ patient lives impacted by portfolio companies
  • +2 more outcomes

Companies that use Arboretum Ventures

Customer profile

Named customers12 records

Segments3 records

Ideal customer profiles2 records

Arboretum Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Arboretum Ventures partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Arboretum Ventures competitors and assessment

Company assessment

Direct peers

  • Hatteras Venture Partners: Mid-size healthcare-focused VC firm based in Durham, NC that invests in early-stage biotech, medtech, and health IT companies. Directly comparable to Arboretum given similar stage focus, fund size, and prior co-investment in Pharaoh Neuro's $20M Series A.
  • Deerfield Management: Healthcare-focused investment firm with multi-strategy private and public healthcare exposure. Comparable to Arboretum as a healthcare-dedicated investor that co-invested in Strata Oncology's Series B and shares the same sector specialization.
  • Baird Capital: Private equity and venture arm of Robert W. Baird with a dedicated healthcare practice. Comparable stage and sector focus, and participated as a co-investor alongside Arboretum in Strata Oncology's $26M Series B.
  • Domain Associates: Healthcare-focused VC firm based in San Diego investing in medical devices, biopharma, and diagnostics. Directly comparable specialty and stage; Arboretum's Venture Partner Nicole Vitullo previously spent 20+ years at Domain.
  • SV Health Investors: Boston and London-based healthcare VC firm investing across biotech, medical devices, and health tech. Comparable stage and sector focus as Arboretum with similar fund size and Series A/B orientation.

Regional players

  • Renaissance Venture Capital Fund: Michigan-based venture capital fund of funds and co-investor that participated in Strata Oncology's Series B alongside Arboretum. Comparable as a regional Michigan investor with healthcare exposure but operates more as a fund-of-funds.

Broad incumbents

  • New Enterprise Associates (NEA): One of the largest US venture firms with a substantial healthcare and life sciences practice. Comparable sector focus but materially larger AUM and broader stage range than Arboretum.
  • ARCH Venture Partners: Healthcare and technology VC firm with deep life sciences and biotech franchise. Comparable as a healthcare specialist but operates at materially larger fund sizes than Arboretum.
  • Pfizer Ventures: Corporate venture arm of Pfizer investing in early-stage biotech, medtech, and digital health. Co-investor with Arboretum in Strata Oncology's Series B; broader portfolio and significantly larger check capacity.
  • Merck Global Health Innovation Fund: Corporate venture arm of Merck investing across digital health, health tech, and life sciences. Co-investor alongside Arboretum in Strata Oncology's Series B; operates at far larger scale as a strategic CVC.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Arboretum Ventures social profiles

Digital presence

Arboretum Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arboretum Ventures leadership team

Management profile

Number of profiles

Profiles16 records

Arboretum Ventures funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arboretum Ventures M&A and investment

M&A and investment

M&A

Investments115 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arboretum Ventures

What does Arboretum Ventures do?

Arboretum Ventures is a Michigan-based venture capital firm that provides early-stage (Series A and B) growth capital to healthcare companies across four sectors: Medical Devices, Life Science Tools & Diagnostics, Tech-Enabled Care Delivery, and Pharma Adjacencies. The firm manages $1B across six funds, deploys capital primarily into under-ventured geographies, and provides strategic guidance, board participation, and network access to portfolio companies. Capital is sourced from institutional Limited Partners (pension funds, endowments, family offices) via multi-year fund commitments.

Is Arboretum Ventures a public or private company?

Arboretum Ventures is a private company. It is classified as management employee owned and is currently operating.

When was Arboretum Ventures founded?

Arboretum Ventures was founded in 2002. It employs 11 to 50 people.

Where is Arboretum Ventures based?

Arboretum Ventures is headquartered in Ann Arbor, United States, in the North America region.

How does Arboretum Ventures make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest (Carry).

Who are Arboretum Ventures's main competitors?

Direct peers on record are Hatteras Venture Partners, Deerfield Management, Baird Capital, Domain Associates and SV Health Investors. Renaissance Venture Capital Fund is listed as a regional player. Broad incumbents are New Enterprise Associates (NEA), ARCH Venture Partners, Pfizer Ventures and Merck Global Health Innovation Fund.

Does Arboretum Ventures have an API?

No public API is recorded for Arboretum Ventures.

What industry is Arboretum Ventures in?

Arboretum Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAL, Venture Debt Providers. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFrancis Medical Announces Close of Record $80 Million Series C Equity FinancingFrancis Medical closed an oversubscribed $80 million Series C equity financing, co-led by Arboretum Ventures and Solas BioVentures. Proceeds will fund the VAPOR 2 pivotal clinical study and U.S. commercialization of its Vanquish Water Vapor Ablation therapy, expected by end of 2025. The company expects to file for 510(k) clearance in July 2025.YahooFrancis Medical Announces Close of Record $80 Million Series C Equity FinancingFrancis Medical closed a record $80 million Series C equity financing, co-led by Arboretum Ventures and Solas BioVentures. The funds will support the VAPOR 2 pivotal clinical study and U.S. commercialization of its Vanquish Water Vapor Ablation prostate cancer treatment, expected by end of 2025.Eyes On EyecareOrasis secures financing to support US commercial launch of QlosiOrasis Pharmaceuticals secured $78 million in Series D financing to support the U.S. commercial launch of Qlosi, a prescription eye drop for presbyopia approved by the FDA in October 2023. The round was co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc., with participation from investors including Sequoia Capital and SBI Innovation Fund. This funding will enable Orasis to proceed with marketing its pilocarpine-based product to the eye care community.PR NewswireRareCyte secures $20M financing to expand the Orion™ Spatial Biology platform including Multiplex Assay Reagents, Software and Precision Biology ServicesRareCyte, Inc. announced the completion of a $20 million financing round led by Arboretum Ventures and F-Prime Capital, with new investor Forest Road joining the group. The funds will be used to expand the Orion Spatial Biology platform, commercialize new multiplex assays and software, and grow its Precision Biology Services globally. This investment aims to accelerate the development of spatial biology applications for researchers and drug developers in areas such as immuno-oncology and infectious disease.Venture Capital Access OnlineATACOR MEDICAL CLOSES $28M SERIES C FINANCING TO DELIVER NEXT GENERATION EXTRAVASCULAR ICD AND PACING OPTIONS FOR CARDIAC RHYTHM MANAGEMENTAtaCor Medical Inc. has closed a $28 million Series C financing round led by Arboretum Ventures, with participation from existing investors including Longview Ventures and Hatteras Venture Partners. The company intends to utilize these funds to support FDA submissions for its extravascular temporary pacing lead system and complete a pilot study for its third-generation EV-ICD lead system.PR NewswireATACOR MEDICAL CLOSES $28M SERIES C FINANCING TO DELIVER NEXT GENERATION EXTRAVASCULAR ICD AND PACING OPTIONS FOR CARDIAC RHYTHM MANAGEMENTAtaCor Medical Inc. has closed a $28 million Series C financing round led by Arboretum Ventures to support the development of its extravascular cardiac rhythm management systems. The company plans to utilize these funds for FDA submissions for its temporary pacing lead system and to complete a pilot study for its third-generation EV-ICD lead system.Venture Capital Access OnlineViaLase Closes $40 million Series C Financing to Advance First Femtosecond Laser for the Treatment of GlaucomaViaLase, Inc. has closed a $40 million Series C financing round to advance its clinical and regulatory milestones for the ViaLase Laser, an investigational femtosecond laser for treating primary open angle glaucoma. The funding was led by new investors alongside existing backers including Venture Investors Health Fund, Arboretum Ventures, and Falcon Vision. Proceeds will support the company's efforts to achieve commercialization of this potentially first-in-class noninvasive treatment.AxiosHealth Tech: SSRI alternativeMotif Neurotech raised $18.75 million in Series A funding led by Arboretum Ventures. The Houston-based company develops an implantable brain stimulator for depression, targeting patients who don't respond to SSRIs. Funds will support a first clinical study, with a potential Series B after results.VirtualincisionVirtual Incision Extends Series C Round with Additional $30M FundingVirtual Incision, a Lincoln, Nebraska developer of the MIRA miniaturized robotic-assisted surgery system, announced on September 19, 2023 a $30 million extension to its $46 million Series C round, led by existing investors and new health-tech backers Arboretum Ventures and InVivium Capital. The company plans to fund operations through 2025, including a gynecologic clinical study in 2024 and a first-in-human study next year.Business Wire BlogVirtual Incision Extends Series C Round with Additional $30M FundingVirtual Incision extended its Series C financing by $30 million, led by existing investors and new health-tech firms Arboretum Ventures and InVivium Capital. The funding supports operations through 2025 and a gynecologic clinical study planned for 2024. The company also plans a first-in-human study for a smaller minibot next year.